Emergent BioSolutions (EBS) Debt to Equity (2010 - 2026)

Emergent BioSolutions' Debt to Equity history runs 17 years deep, the most recent figure standing at $1.1 for Q1 2026.

• In Q1 2026, Debt to Equity fell 8.96% year-over-year to $1.1; the TTM figure through Mar 2026 stood at $1.1 (down 8.96% YoY), while the FY2025 annual figure was $1.09, down 20.37% from the prior year.
• Debt to Equity was $1.1 for Q1 2026 at Emergent BioSolutions, roughly flat from $1.09 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $1.37 in Q4 2024 to a low of $0.32 in Q4 2022.
• Historically, Debt to Equity has averaged $0.86 across 5 years, with a median of $0.72 in 2022.
• The sharpest annual moves came in 2022 and 2024: Debt to Equity tumbled 35.65% in 2022, then soared 147.36% in 2024.
• A 5-year view of Debt to Equity shows it stood at $0.32 in 2022, then soared by 112.77% to $0.69 in 2023, then jumped by 99.91% to $1.37 in 2024, then slipped by 20.37% to $1.09 in 2025, then advanced by 0.17% to $1.1 in 2026.
• The last three Debt to Equity figures came in at $1.1 (Q1 2026), $1.09 (Q4 2025), and $1.14 (Q3 2025), per Business Quant data.